This Innovative Biotech Company Is Taking A Novel... Another trading week is behind us!
|
RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older. Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness. This company’s study has achieved an extremely significant result in the fight against RSV!
RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older. Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness. This company’s study has achieved an extremely significant result in the fight against RSV! Learn how this company could see tremendous growth ahead with a novel broad-spectrum antiviral that has activity against RSV! -- | From time to time your free Smart Investing Society newsletter subscription is supplemented by paid sponsorships, like the one above. Please read all disclaimers. Rest assured that your information was not shared with this sponsor. Please note that Smart Investing Society has not independently reviewed the validity of the claims or statements contained within this sponsorship, and we are not responsible for any errors or omissions.
Never invest in a security or idea featured on our site or in our emails unless you can afford to lose your entire investment. We are not registered investment advisors or brokers/dealers and we do not purport to be. We make no representations, warranties or guarantees as to the accuracy or completeness of the content featured on our site or in our emails. Furthermore, the article authors and contributors featured on this site may own securities mentioned in their articles and not disclose this information. Smart Investing Society does not endorse any investing or trading products or newsletters advertised in this email or on our web site. Please be sure to read our
| Go here to get more information from
| |
|